BRKR Stock Cash Flow Statements

Bruker Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Bruker Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-09-30	2018-06-30	2018-03-31	2017-09-30	2017-06-30	2017-03-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2011-09-30	2011-06-30	2011-03-31	2010-09-30	2010-06-30	2010-03-31	2009-09-30	2009-06-30	2009-03-31	2008-09-30	2008-06-30	2008-03-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30

cash flows from operating activities:
consolidated net income	4,200,000	16,800,000				204,600,000	88,700,000	57,800,000	77,400,000	98,300,000	88,400,000	49,700,000	62,100,000	76,000,000	88,100,000	58,700,000	57,800,000	71,300,000	55,300,000	24,200,000	10,600,000	68,800,000	61,500,000	37,000,000	30,700,000	44,200,000	31,500,000	27,400,000	37,600,000	24,000,000	21,700,000	47,000,000	14,800,000	23,600,000	12,900,000	23,100,000	6,900,000	6,300,000	16,800,000	10,000,000	16,900,000	23,300,000	5,700,000	39,900,000	9,900,000	15,100,000	20,100,000	22,600,000	11,700,000	27,900,000	22,900,000	16,000,000		12,700,000	8,600,000
adjustments to reconcile net income to cash flows from operating activities:
depreciation and amortization	56,100,000	50,400,000	51,000,000	45,200,000	34,700,000	37,300,000	26,600,000	25,900,000	25,100,000	24,500,000	21,000,000	21,600,000	21,700,000	23,000,000	22,200,000	21,600,000	22,300,000		20,500,000	19,200,000	19,000,000		18,900,000	19,400,000	19,000,000	15,900,000	16,600,000	15,800,000	17,100,000	16,000,000	15,100,000	13,700,000	13,500,000	13,200,000	13,300,000	13,200,000	13,500,000	17,600,000	14,800,000	15,200,000	15,200,000	15,000,000	15,200,000	13,900,000	15,000,000	13,600,000	13,600,000	13,800,000	11,900,000	9,100,000	7,200,000	7,500,000	7,100,000	7,000,000	6,800,000
deferred income taxes	-15,900,000	-22,700,000	-21,900,000	-20,200,000	-2,100,000	-37,200,000	3,400,000	8,200,000	1,200,000	10,900,000	-17,500,000	-4,200,000	-4,000,000	700,000	-2,700,000	-8,700,000	4,900,000		1,600,000	-2,200,000	1,100,000		-200,000								400,000								0	300,000
other non-cash expenses	-11,600,000	11,200,000			-6,100,000	13,800,000	2,300,000	11,000,000	5,000,000	6,500,000	7,900,000	10,100,000	-6,200,000	2,100,000	4,000,000	15,900,000	4,900,000		6,300,000	7,500,000	11,700,000		-4,400,000	1,600,000	4,500,000	-8,900,000	6,600,000	18,200,000	4,300,000	500,000	1,300,000	3,700,000	7,300,000	1,700,000	8,600,000	-6,400,000	7,300,000	9,900,000	500,000	700,000									600,000
changes in operating assets and liabilities, net of acquisitions and divestitures:
income taxes payable			5,000,000	-10,500,000	-11,900,000	57,200,000	4,300,000	-12,000,000	-5,800,000	-17,400,000	27,100,000	-17,100,000	600,000	-10,900,000	-40,400,000	-3,100,000	10,100,000		-6,000,000	11,900,000	-15,000,000		12,800,000																6,800,000	2,000,000
other changes in operating assets and liabilities			8,000,000	-12,300,000	-30,300,000	25,400,000	-12,400,000	-20,900,000	-20,200,000	15,900,000	200,000	-15,300,000	1,800,000	31,300,000	-20,300,000	-13,100,000	-17,100,000		-1,600,000	10,200,000	-20,400,000		-10,300,000					2,300,000	2,700,000	-2,800,000	5,500,000																			24,300,000
net cash from operating activities	-127,500,000	65,000,000	38,400,000	1,100,000	21,800,000	205,500,000	44,100,000	13,000,000	87,500,000	171,500,000	69,500,000	-44,400,000	77,800,000	138,600,000	23,900,000	21,900,000	98,000,000	203,000,000	82,400,000	11,800,000	35,000,000	136,200,000	52,400,000	10,600,000	14,200,000	27,500,000	36,100,000	43,800,000	35,300,000	-17,200,000	32,600,000	35,900,000			54,100,000	-1,500,000	27,000,000	13,500,000	13,000,000	18,500,000				300,000						9,600,000	47,600,000	5,500,000	16,000,000	38,200,000	13,100,000	899,000	-4,230,000	22,333,000	-3,797,000	-6,807,000	451,000	19,858,000	17,575,000	1,935,000	-1,675,000	-25,535,807	3,918,000
capex	-21,300,000	-26,000,000	-32,600,000	-24,600,000	-21,400,000	-31,500,000	-26,900,000	-23,500,000	-25,000,000	-34,600,000	-57,700,000	-17,900,000	-19,000,000	-28,400,000	-16,300,000	-22,600,000	-24,700,000	-28,800,000	-17,600,000	-20,300,000	-30,500,000	-28,200,000	-16,200,000	0	0	0	0	0	0	0	0	0			0	0	0	0	0	0				0						0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
free cash flows	-148,800,000	39,000,000	5,800,000	-23,500,000	400,000	174,000,000	17,200,000	-10,500,000	62,500,000	136,900,000	11,800,000	-62,300,000	58,800,000	110,200,000	7,600,000	-700,000	73,300,000	174,200,000	64,800,000	-8,500,000	4,500,000	108,000,000	36,200,000	10,600,000	14,200,000	27,500,000	36,100,000	43,800,000	35,300,000	-17,200,000	32,600,000	35,900,000			54,100,000	-1,500,000	27,000,000	13,500,000	13,000,000	18,500,000				300,000						9,600,000	47,600,000	5,500,000	16,000,000	38,200,000	13,100,000	899,000	-4,230,000	22,333,000	-3,797,000	-6,807,000	451,000	19,858,000	17,575,000	1,935,000	-1,675,000	-25,535,807	3,918,000
cash flows from investing activities:
purchases of property, plant and equipment	-21,300,000	-26,000,000	-32,600,000	-24,600,000	-21,400,000	-31,500,000	-26,900,000	-23,500,000	-25,000,000	-34,600,000	-57,700,000	-17,900,000	-19,000,000	-28,400,000	-16,300,000	-22,600,000	-24,700,000	-28,800,000	-17,600,000	-20,300,000	-30,500,000	-28,200,000	-16,200,000
cash paid for acquisitions, net of cash acquired	-68,400,000	-1,100,000	-200,000	-1,302,000,000	-274,500,000	-4,300,000	-119,600,000	-14,600,000	-88,100,000	-96,800,000	-100,000			-20,000,000	-41,000,000	0	-4,000,000
other investing activities	-1,400,000	1,000,000
net cash from investing activities	-91,100,000	-26,100,000	-67,600,000	-1,324,900,000	-304,200,000	-36,800,000	-155,000,000	-26,000,000	-108,200,000	-149,300,000	-57,600,000	57,100,000	-101,800,000	-48,600,000	-48,400,000	-71,400,000	-24,000,000	-28,800,000	-48,200,000	-15,100,000	-100,600,000	-39,200,000	-12,600,000			-29,100,000	-46,100,000	108,100,000																																		-1,406,000	-26,820,000	27,191,000	13,334,000
cash flows from financing activities:
repayments of revolving line of credit	-51,200,000	-167,900,000	-148,500,000	-839,600,000	-500,000
proceeds from revolving line of credit	168,300,000	139,900,000	100,000	804,400,000	268,900,000
repayment of long-term debt	-14,600,000	-7,700,000			-3,400,000
proceeds from long-term debt	0	2,900,000					400,000
proceeds from issuance of common stock	4,900,000	400,000			3,400,000	4,700,000	2,000,000	2,100,000	700,000	2,000,000	-2,500,000	200,000	3,100,000	1,100,000	3,700,000	1,100,000	1,100,000								3,100,000	1,900,000	4,400,000	2,600,000	6,100,000	8,000,000	1,200,000	600,000	2,100,000	7,500,000	800,000	2,900,000	3,300,000	2,500,000	1,800,000	3,000,000	3,500,000	400,000	4,100,000	200,000	1,600,000	1,800,000	100,000	500,000	2,500,000										447,000	455,000	17,962,000		369,000	40,000	9,000		202,000
payment of dividends to common shareholders	-7,600,000	-7,700,000	-7,600,000	-7,700,000	-7,300,000	-7,300,000	-7,400,000	-7,300,000	-7,400,000	-7,400,000
repurchase of common stock	0	-10,000,000				-50,400,000	-79,500,000	0	-22,400,000	-26,300,000	-70,900,000	-60,300,000	-105,600,000
other financing activities	-4,300,000	-1,100,000
net cash from financing activities	95,500,000	-51,200,000	-2,700,000	1,155,800,000	151,700,000	-59,900,000	-92,500,000	-10,300,000	-30,700,000	-36,100,000	-82,000,000	-79,800,000	-217,400,000	404,300,000	-2,600,000	-44,900,000	-38,100,000		-225,500,000	-53,100,000	191,300,000		-19,500,000														4,100,000	3,000,000	700,000	2,500,000	22,100,000	2,400,000	300,000	15,700,000														355,935,000	4,509,000	-806,000	7,183,000			-565,000	1,250,000
effect of exchange rate changes on cash, cash equivalents and restricted cash	31,600,000	13,300,000	10,400,000	-2,100,000	-17,600,000	15,900,000	-7,900,000	100,000	4,100,000	33,300,000	-26,900,000	-26,200,000	-10,700,000	900,000	-8,100,000	5,700,000	-21,000,000		11,500,000	7,900,000	-8,700,000		-6,800,000					5,800,000	2,700,000	6,900,000	5,800,000
net decrease in cash, cash equivalents and restricted cash
cash, cash equivalents and restricted cash at beginning of period	0	186,700,000	0	0	491,600,000		0	0	648,700,000		0	0	1,071,700,000		0	0	685,500,000		0	0	681,900,000		0	0	326,300,000	0	0	328,900,000	0	0	345,900,000
cash, cash equivalents and restricted cash at end of period	-91,500,000	187,700,000	-21,500,000	-170,100,000	343,300,000		-211,300,000	-23,200,000	601,400,000		-97,000,000	-93,300,000	819,600,000		-35,200,000	-88,700,000	700,400,000		-179,800,000	-48,500,000	798,900,000		13,500,000	-16,100,000	302,600,000	12,300,000	-25,300,000	287,800,000	46,400,000	-59,300,000	280,700,000
supplemental disclosure of cash flow information:
cash paid for interest
cash paid for taxes
restricted cash period beginning balance	0	3,300,000	0	0	3,300,000	0	0	0	3,200,000	0	0	0	3,500,000	0	0	0	3,700,000	0	0
restricted cash period ending balance	700,000	3,500,000	100,000	300,000	3,200,000	0	-100,000	-100,000	3,500,000	100,000	-200,000	-200,000	3,500,000	0	-100,000	0	3,600,000	200,000	-100,000
changes in operating assets and liabilities, net of acquisitions and divestitures		9,300,000
net increase in cash, cash equivalents and restricted cash		1,000,000
net income			40,300,000	7,600,000	52,000,000
stock-based compensation expense			6,300,000	6,900,000	5,300,000	6,200,000	5,700,000	5,600,000	6,500,000	4,700,000	5,300,000	9,700,000	8,000,000	5,300,000	4,200,000	3,900,000	3,800,000		4,500,000	3,100,000	3,300,000		4,000,000	3,000,000	3,100,000	3,300,000	2,400,000	2,500,000	3,100,000	2,700,000	2,600,000	2,500,000	2,100,000	2,200,000	2,200,000	1,400,000	2,200,000	2,100,000	3,000,000	2,000,000	1,600,000	1,400,000	1,800,000
impairment of minority investments and other long-lived assets			5,900,000	20,200,000	1,400,000				6,900,000
gain on sale of minority investment
gain on sale of property, plant and equipment			1,700,000			900,000	200,000	200,000	-9,800,000
other non-cash incomes			2,500,000
accounts receivable			-18,800,000	13,900,000	15,600,000	11,500,000	-42,900,000	22,200,000	8,300,000	-28,200,000	-35,300,000	-2,000,000	-2,400,000	-47,600,000	-39,200,000	-9,300,000	800,000		2,600,000	4,800,000	29,500,000		-18,600,000				26,600,000	10,000,000		-8,700,000	25,600,000	-14,900,000	23,100,000	7,200,000	-4,900,000	-8,900,000	51,500,000	-7,400,000	16,100,000	12,800,000			8,700,000	-11,400,000	7,700,000	28,900,000					4,900,000	4,500,000	-13,400,000	19,700,000	20,600,000
inventories			-11,100,000	-29,200,000	-64,800,000	22,300,000	-32,900,000	-59,400,000	-55,000,000	1,200,000	-34,500,000	-55,600,000	-49,000,000	14,300,000	-13,000,000	-26,700,000	-41,600,000		-12,700,000	-36,000,000	-61,000,000		-11,100,000
accounts payable and accrued expenses			20,900,000	9,300,000	-3,700,000	12,000,000	14,500,000	-16,500,000	13,100,000	12,900,000	17,600,000	-17,200,000	-100,000	15,500,000	32,900,000	-22,500,000	35,500,000		800,000	-35,200,000	19,100,000		7,500,000	-8,200,000	11,000,000													15,800,000	-13,000,000	21,900,000
deferred revenue and customer advances			-51,400,000	-29,600,000	31,700,000	-7,100,000	-14,600,000	-13,700,000	34,800,000
proceeds from sale of minority investment
cash paid for minority investments			-36,000,000	0	-10,000,000
proceeds from sales of property, plant and equipment			0	400,000	500,000	200,000	200,000	0	10,700,000	100,000	0	1,100,000	12,700,000	900,000	1,600,000	1,200,000	1,200,000					0	10,700,000			0			0	300,000	6,600,000	0	300,000	600,000	0			1,800,000
net proceeds from cross-currency swap agreements			1,200,000	1,300,000	1,200,000	1,300,000	1,300,000	1,400,000	2,400,000	1,400,000	2,900,000						3,500,000
repayment of other debt			-6,000,000				-2,500,000	-2,400,000	-2,100,000		-300,000	-500,000	-400,000	-100,000	-500,000	-1,300,000	-400,000
proceeds from 2024 note purchase agreements			0
proceeds from 2024 term loan agreements			166,100,000
proceeds from other long-term debt			700,000
repayment of 2012 note purchase agreement			0	0	-100,000,000					0	0	0	-105,000,000
repayment of 2019 term note agreement			-3,800,000	-3,700,000	-3,800,000
payment of deferred financing costs			0	-800,000	-4,700,000
proceeds from public offering of common stock, net of issuance costs			100,000
proceeds from issuance of common stock under employee stock plans			-2,900,000
payment of contingent consideration			-900,000			0	-200,000	-1,500,000	-1,000,000	-1,000,000	3,100,000	-3,600,000	-1,200,000	0	0	0	-400,000
proceeds from (payment for) the sale (purchase) of noncontrolling interests			0	-100,000	-900,000	-500,000	-1,500,000
net (decrease) in cash, cash equivalents and restricted cash
net change in cash, cash equivalents and restricted cash				-170,100,000	-148,300,000	124,700,000	-211,300,000	-23,200,000	-47,300,000	19,400,000	-97,000,000	-93,300,000	-252,100,000	495,200,000	-35,200,000	-88,700,000	14,900,000		-179,800,000	-48,500,000	117,000,000		13,500,000
adjustments to reconcile consolidated net income to cash flows from operating activities:
bargain purchase gain on acquisition
changes in operating assets and liabilities, net of acquisitions:
purchases of short-term investments															0				-50,000,000	0	-50,000,000		0
maturity of short-term investments										0	0			97,500,000																							21,500,000
proceeds from issuance (repayment) of long-term debt
repayment of 2019 term loan agreement
cash, cash equivalents and restricted cash at beginning of year
cash, cash equivalents and restricted cash at end of year
supplemental cash flow information:
impairment of strategic investments and other long-lived assets							1,200,000
gain on sale of strategic investment							0
proceeds from sale of strategic investment							0
cash paid for strategic investments							-10,000,000	-1,100,000	-8,200,000	-19,400,000	-2,700,000
repayment of 2019 note purchase agreement							-3,800,000	-3,700,000	-3,800,000	-3,700,000	-800,000	-700,000	-800,000
proceeds from the sale of noncontrolling interests									5,300,000
deferred revenue										10,400,000	-2,400,000	-6,300,000	22,700,000	900,000	-600,000	5,900,000	14,100,000		500,000	-1,000,000	20,600,000		500,000	-4,700,000	13,900,000	-4,900,000	3,800,000	5,900,000		2,400,000	900,000	-2,400,000	-3,800,000	9,200,000				300,000	-3,100,000	5,000,000	-3,700,000	2,100,000	2,900,000
customer advances										31,800,000	-8,300,000	-17,800,000	22,600,000	28,000,000	-11,300,000	-700,000	2,500,000		10,600,000	5,300,000	16,500,000		-8,200,000	-7,400,000	6,500,000			17,800,000									8,900,000						3,700,000						13,800,000						5,900,000
proceeds from issuance of long-term debt
repayments of revolving lines of credit
proceeds from revolving lines of credit																									40,600,000	20,000,000			75,000,000	46,000,000	33,000,000	22,000,000	41,000,000	36,000,000	7,000,000
proceeds (repayment) of other debt																																-100,000	-200,000	400,000
purchase of minority interest										-1,200,000	-3,200,000
payment of dividends to common stockholders												-7,500,000	-7,500,000	-6,000,000	-6,100,000	-6,000,000	-6,100,000
cash paid for strategic investments, at cost													-12,000,000
cash paid for acquisitions; net of cash acquired													-83,800,000
net proceeds from cross currency swap agreements													300,000		7,100,000				3,600,000
purchase of short-term investments
purchase of investments held to maturity
cash payments to noncontrolling interests
purchases of investments held to maturity
proceeds from other debt															300,000	-200,000	300,000
purchases of common stock															0	-38,500,000	-32,600,000
cash payments to noncontrolling interest
impairment and other non-cash expenses
purchase of available for sale debt securities
proceeds from 2019 note purchase agreement
proceeds from 2019 term loan agreement

maturities of short-term investments																										0	0	117,000,000	64,600,000	10,700,000	58,700,000	72,300,000	28,400,000	21,700,000	1,000,000
repayments of 2012 note purchase agreement
proceeds of other debt																									200,000
payment of dividends
supplemental disclosure of cash flow information
net proceeds from cross- currency swap agreements																					1,900,000
repayments of note purchase agreement
write-down of inventories to net realizable value																																													7,300,000	6,800,000
repayments of the note purchase agreement
(repayment) proceeds of other debt
excess tax benefit related to stock option awards
write-down of demonstration inventories to net realizable value																															2,800,000	4,000,000	3,700,000	4,800,000	5,100,000	4,900,000	5,000,000	7,400,000	7,600,000	7,600,000	8,000,000	8,200,000	7,800,000
loss on disposal of product line
changes in restricted cash																																-100,000			0	600,000	800,000
excess tax benefits related to stock option awards																																0			0	0	2,200,000
effect of exchange rate changes on cash and cash equivalents																																1,900,000	-1,200,000	5,800,000						2,200,000								5,000,000	6,500,000			200,000				-10,520,000
net change in cash and cash equivalents																																			10,200,000	-13,700,000	15,000,000			15,300,000																					3,545,000			29,896,000	13,541,000	-17,625,388	3,299,000
cash and cash equivalents at beginning of period																																0	0	267,100,000	0	0	319,500,000	0	0	438,700,000	0	0	310,600,000	0	0	246,000,000	0	0	230,400,000	0	0	207,100,000	0	0	166,200,000	0	0	332,368,000	0	0	52,147,000		9,473,000	0	53,159,000
cash and cash equivalents at end of period																																46,200,000	22,600,000	209,900,000	10,200,000	-13,700,000	334,500,000	-60,600,000	-64,200,000	454,000,000	55,900,000	-18,500,000	269,400,000	1,800,000	10,800,000	229,500,000	26,000,000	-23,500,000	193,300,000	400,000	-15,500,000	203,100,000	-4,100,000	4,200,000	148,400,000	-41,018,000	-172,864,000	298,263,000	-3,029,000	-13,759,000	55,692,000		-52,445,000	29,896,000	66,700,000
gain on disposal of product line																																			0
proceeds from disposal of product line																																						12,100,000
sales of property, plant and equipment																																								600,000	200,000	0	600,000	800,000
disposal of product line																																								700,000	0	0	500,000
proceeds from note purchase agreement																																												0	0	240,000,000
amortization of deferred financing costs																																												200,000	100,000	200,000	100,000	200,000	100,000	200,000	100,000	200,000
stock-based compensation																																												2,100,000	1,900,000	1,900,000	2,000,000	2,000,000	1,800,000	1,700,000	1,700,000	1,600,000	1,500,000	1,500,000	1,800,000
gain on disposal of business
other non-cash expense																																												800,000	-1,000,000	1,800,000	400,000			-1,200,000
changes in operating assets and liabilities:
acquisitions, net of cash acquired
disposal of business
(repayments) proceeds of revolving lines of credit
non-cash financing activities:
issuance of common stock in connection with acquisition of michrom bioresources inc.																																															0
accounts payable																																													-6,800,000	10,800,000	-1,400,000	-1,300,000	14,300,000	1,500,000	3,400,000	5,900,000			6,600,000
customer deposits																																														25,700,000	4,600,000					6,100,000
net cash from (used) in operating activities																																														4,800,000
repayment of term debt and capital leases
net cash from (used) in financing activities																																														14,800,000
write down of inventories to net realizable value																																															11,000,000
loss on divestiture of business
net cash (used) in provided by operating activities
proceeds (repayments) of revolving lines of credit
repayment of term debt
write down of demonstration inventories to net realizable value																																																	6,500,000
gain on bargain purchase
issuance of common stock under stock plans																																																		500,000	600,000	1,600,000
other non-cash income
net income attributable to bruker corporation
gain on acquisition
redemption of short-term investments																																																										742,000						29,301,000	17,159,000
payments in connection with the acquisition of bruker biospin
proceeds from (repayments of) short-term borrowings																																																								-11,302,000	9,542,000	5,554,000
proceeds from (repayments of) long-term debt																																																								-9,358,000	-175,008,000	353,297,000
proceeds from issuance of common stock, net of repurchases																																																					500,000
deemed dividend in connection with the acquisition of bruker biospin
cash payments to shareholders
effective of exchange rate changes on cash and cash equivalents
operating activities:
adjustments to reconcile net income to cash flow from operating activities:
other noncash reconciling items
investing activities:
payments in connection with the acquistion of bruker biospin
proceeds from sale of short-term investments																																																								-189,000
financing activities:
payments of deferred financing costs
deemed dividend in connection with the acquistion of bruker biospin
purchases of property and equipment
effect of exchange rate changes on cash																																																										28,215,000	1,774,000	299,000	441,000	746,000	1,195,000	1,335,000	632,000
(repayments of) proceeds from short-term borrowings
(repayments of) proceeds from long-term debt
non-cash financing activities
issuance of common stock related to acquisitions																																																											0
repayments of long-term debt
write down of investments and other non-cash charges
benefit from doubtful accounts
stock compensation
minority interest in consolidated subsidiary
gain on disposal of assets
(gain) loss on fair market value of derivative instruments
other assets and prepaid expenses
accrued pension
other liabilities
restricted cash
proceeds from (repayment of) short-term borrowings
proceeds from issuance of common stock, net of issuance costs
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
noncash investing and financing activities:
issuance of common stock for bruker optics acquisition
issuance of common stock for other acquisitions
sales of short-term investments
proceeds from (payments of) short-term borrowings
proceeds from (payments of) long-term debt
payments to shareholders
proceeds from short-term borrowings																																																																100,000	1,459,000
other special charges
loss on disposal of assets
reversal of patent litigation settlement
foreign currency exchange gain on intercompany loans
issuance of long-term debt
issuance of common stock for acquisition
issuance of common stock and options exchanged related to merger
purchases (redemptions) of short-term investments
cash, cash equivalents and short-term investments at beginning of period																																																																			0
cash, cash equivalents and short-term investments at end of period																																																																			3,299,000
proceeds (repayment) of short-term borrowings
proceeds (repayment) of long-term debt

We provide you with 20 years of cash flow statements for Bruker stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Bruker stock. Explore the full financial landscape of Bruker stock with our expertly curated income statements.

The information provided in this report about Bruker stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.